Metfonorm (Metformin Hydrochloride)

Metfonorm, a biguanide antidiabetic, acts on glucose metabolism pathways to lower blood sugar levels.

• Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c.
• Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes.
• Metabolic syndrome: contributes to better insulin sensitivity and modest weight reduction.

• Metformin Hydrochloride decreases hepatic gluconeogenesis, enhances peripheral glucose uptake, and improves insulin sensitivity by activating AMP‑activated protein kinase (AMPK). This results in reduced hepatic glucose output and increased utilization of glucose by muscle and adipose tissue, thereby lowering plasma glucose concentrations.

Metfonorm may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often early in therapy.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal metabolic acidosis.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Hypoglycemia: usually when combined with other antidiabetics.
• Anemia: due to B12 deficiency.
• Pancreatitis: very uncommon inflammation of the pancreas.

When prescribing Metfonorm, clinicians should consider several safety aspects.

• Renal function: assess eGFR before initiation and periodically thereafter.
• Hepatic impairment: use with caution in patients with liver disease.
• Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia.
• Vitamin B12 monitoring: check levels during long‑term therapy.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Store below 25°C: keep in the original pack, protect from moisture.

Metfonorm can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging.
• Cimetidine: may raise metformin plasma concentrations.
• Alcohol excess: potentiates lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics: can affect renal clearance of metformin.
• Warfarin: may require INR monitoring due to possible interaction.